Nanotherapeutic platforms, such as the BRAFi/COX2i-loaded nanogel Cyclic di-nucleotide phosphodiesterase (CDNP), induce pyroptosis and remodel the TME, leading to superior tumor control when combined with anti-PD1 therapy (206). This evidence concerns the gene PDCD1 and neoplasm.